Share, email, print, bookmark SOURCE reports.

In full transparency, the following is a press release submitted to SOURCE media for publication.


[broadstreet zone=”59983″]

BOSTON – Reproductive Equity Now President Rebecca Hart Holder released the following statement today, March 22 after the Massachusetts Board of Registration in Pharmacy issued guidance requiring pharmacies in the Commonwealth to stock and dispense all reproductive health care medications, including mifepristone, the first drug used in a two-drug medication abortion regimen.

This announcement comes after Walgreens retracted its public commitment earlier this month to stock mifepristone after 20 anti-abortion attorneys general threatened legal action against the retail pharmacy chain.

Mifepristone is a safe, effective, and widely popular drug used to end an early pregnancy. Attacks on mifepristone by anti-abortion extremists are not only unfounded, they are callous attempts to restrict abortion access and reproductive freedom in states like ours that have protected care,” said Rebecca Hart Holder, President of Reproductive Equity Now. “We are proud to see the Healey-Driscoll administration remind pharmacies in Massachusetts that all family planning medications, including mifepristone, must be stocked to meet the needs of the community. We hope this means every pharmacy in our Commonwealth, including Walgreens and CVS, will move to quickly become certified to dispense mifepristone.”

[broadstreet zone=”59984″]

By editor

Susan Petroni is the former editor for SOURCE. She is the founder of the former news site, which as of May 1, 2023, is now a self-publishing community bulletin board. The website no longer has a journalist but a webmaster.